

☒

+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Filed Concurrently Herewith
				First Named Inventor	STUTZMANN
				Group Art Unit	1623
				Examiner Name	L. Maier
				Attorney Docket Number	ST00001 - US - CNT
Sheet	1	of	4		

[illegible][illegible]

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
-----------------------	---------------	--------------------	------------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/088 (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Filed Concurrently Herewith
		First Named Inventor	STUTZMANN
		Group Art Unit	1623
		Examiner Name	L. Maier
Sheet	2	of	4
		Attorney Docket Number	ST00001 - US - CNT

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		*AGG. TURPIE et al, THE LANCET; 1987; pp. 523-526	
LM		*BATH et al, Low Molecular Weight Heparin in Acute Stroke, EXPERT OPINION INVEST. DRUGS; Vol. 7; No. 8; 1998; pp. 1323-1330	
LM		*DAHL Trond et al, Dalteparin in Acute Ischemic Cerebrovascular Disease: A Safety Study, CEREBROVASCULAR DISEASES; Vol. 7; No. 1; 1997; pp. 23-33	
		<del>*ELIAS et al, LA REVUE DE MEDECINE INTERNE; T; Vol. XI; 1990; pp. 95-98</del>	
LM		FAREED J et al, Biochemical and Pharmacologic Inequivalence of Low Molecular Weight Heparins, Ann. NY Acad. Sci., Vol. 556, 1989, pp 333-353	
LM		*GORDON David Lee et al., Low Molecular Weight Heparins and Heparinoids and Their Use in Acute or Progressing Ischemic Stroke, CLIN. NEUROPHARMACOL.; Vol. 13; No. 6; 1990; pp. 522-544	
LM		*HARDENBERG et al, Enoxaparin Is Superior to Unfractionated Heparin in the Prevention of Thromboembolic Events in Medical Patients at Increased Thromboembolic Risk, BLOOD; Vol. 94; No. 10pt1.suppl.1; Abstract 1767; 1999; pp. 399a	
LM		*HILLBORN M et al, Comparison of the Efficacy of the Low Molecular Weight Heparin Enoxaparin with Unfractionated Heparin in the Prevention of Deep vein Thrombosis in Patients with a Cerebral Ischemic Stroke, BLOOD; Vol. 94; No. 20. Supl. pt1; abstract no.798; Nov. 15,1999; pp. 183a	
LM		*JIANYOU et al, Low-Mol.-Wt. Heparin in Treatment of Acute Cerebral Infarction, CHEMICAL ABSTRACTS; Vol. 127; No. 24; Abstract No. 326219z; 1997; pp. 54	
LM		JONAS S et al, Is Low Molecular Weight Heparin a Neuroprotectant, Annal New York Academy of Sciences, Vol. 825, Oct. 1997, pp 389-393	

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	Not Yet Assigned
		Filing Date	Filed Concurrently Herewith
		First Named Inventor	STUTZMANN
		Group Art Unit	1623
		Examiner Name	L. Maier
		Attorney Docket Number	ST00001 - US - CNT
Sheet	3	of	4

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		*KAY et al, Low-Molecular-Weight Heparin for the Treatment of Acute Ischemic Stroke, NEW ENGLAND J. MED.; Vol. 333; No. 24; 1995; pp. 1588-1593	
LM		*KAY et al, Pilot Study of Low Molecular Weight Heparin in the Treatment of Acute Ischemic Stroke, STROKE; Vol. 25; No. 3; 1994-03; pp. 684-685	
LM		*LI Ping-An et al., Posttreatment with Low Molecular Weight Heparin Reduces Brain Edema and Infarct Volume in Rats Subjected to Thrombotic Middle Cerebral Artery Occlusion, BRAIN RES.; Vol. 801; No. 1-2; 1998; pp. 220-223	
LM		*PRATT J et al., Enoxaparin reduces cerebral edema after photothrombotic injury in the rat, HAEMOSTASIS, 1998, Vol. 28, pages 78-85	
LM		*PRINS et al, Prophylaxis of Deep Venous Thrombosis with a Low Molecular Weight Heparin (Kabi 2165/Fagmin) in Stroke Patients, HAEMOSTASIS; Vol. 19, No. 5; 1989; pp. 245-250	
LM		*RYU et al, Heparin Reduces Neurological Impairment After Cerebral Air Embolism in the Rabbit, STROKE; Vol. 27; No. 2; 1996; pp. 303-310	
LM		*SAMANA M M et al., Acute Ischemic Stroke and Heparin Treatments, THROMB. HAEMOSTASIS; Vol. 78; No. 1; 1997; pp. 173-179	
LM		*STULLKEN ET AL, The Effects of Heparin on Recovery from Ischemic Brain Injuries in Cats, ANESTH. ANALOG; Vol. 55; No. 5; 1976; pp. 683-687	
		<del>*TAIST INVESTIGATORS, Tinzaparin in Acute Ischemic Stroke Trial (TAIST), STROKE; Vol. 30; No. 1; 1999-01; pp. 163</del>	
LM		*YANAKA et al , Reduction of Brain Injury Using Heparin to Inhibit Leukocyte Accumulation in a Rat Model of Transient Focal Cerebral Ischemia. II. Dose-Response Effect and the Therapeutic Window, J. NEUROSURG.; Vol. 85, No. 6; 1996; pp. 1108-1112	

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
--------------------	---------------	-----------------	------------

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	Not Yet Assigned
				Filing Date	Filed Concurrently Herewith
				First Named Inventor	STUTZMANN
				Group Art Unit	1623
				Examiner Name	L. Maier
Sheet	4	of	4	Attorney Docket Number	ST00001 - US - CNT

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		*ZHENG Jinzhi, Clinical Study on Low-Mol.-Wt. Heparin (LLMWH) for Treatment of Acute Cerebral Infarction, CHEMICAL ABSTRACTS; Vol. 130; No. 1; Abstract No. 366b; 1999; pp. 44	
LM		*, Physicians' Desk Reference, 49th Edition, pages 1968-1969, 1995	

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



Please type a plus sign (+) inside this box → ☒

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-98)

Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

1

of

1

### Complete If Known

Application Number	10/849,356
Filing Date	05-19-2004
First Named Inventor	MARY
Group Art Unit	1623
Examiner Name	L. Maier
Attorney Docket Number	ST00001 - US - CNT

### OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		ADACHI et al, Alleviation of ischemic neuronal damage by postischemic loading with histidine in the rat striatum, Brain Res., Vol. 998, Issue 1, Feb., 2004, pp 136-138	
LM		CLARK et al, Reperfusion Following Focal Stroke Hastens Inflammation and Resolution of Ischemic Injured Tissue, Brain Res., Bull. Vol. 34, Issue 4, 1994, pp 387-392	
LM		DIETRICK, Morphological Manifestations of Reperfusion Injury In Brain, Ann. N.Y. Acad. Sci., Vol. 15, Issue 24, June, 1994, pp 15-24	
LM		KOGURE et al, Inflammation of the Brain after Ischemia, Acta Neurochir Suppl (Wien), Vol. 66, 1996, pp 40-43	
LM		McINTOSH et al, Effect of Noncompetitive Blockade of N-Methyl-D-Aspartate Receptors on the Neurochemical Sequelae of Experimental Brain Injury, Journal of Neurochemistry, Vol. 55, Issue 4, 1990, pp 1170-1179	
LM		TOULMOND et al, Prevention by eliprodil (SL 82.0715) of traumatic brain damage in the rat. Existence of a large (18 h) therapeutic window, Brain Res., Vol. 620, 1993, pp 32-41	
LM		ZHANG et al, Aminoguanidine Ameliorates and L-Arginine Worsens Brain Damage From Intraluminal Middle Cerebral Artery Occlusion, Stroke, Vol. 27, No. 2, February, 1996, pp 317-323	

Examiner  
Signature

/Leigh Maier/

Date

Considered

07/06/2006

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

☒

+

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

SEP 12 2005  
DISCLOSURE  
BY APPLICANT  
PRIORITY & TRADEMARK OFFICE

(use as many sheets as necessary)

**Complete if Known**

<b>Application Number</b>	10/849,356
<b>Filing Date</b>	05-19-2004
<b>First Named Inventor</b>	MARY, et. al.
<b>Group Art Unit</b>	1623
<b>Examiner Name</b>	Not Yet Assigned
<b>Attorney Docket Number</b>	ST00001 - US - CNT

[illegible][illegible]

Date Considered	07/06/2006
-----------------	------------

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

+

Please type a plus sign (+) inside this box → ☒

PTO/SB/08B (10-96)  
Approved for use through 10/31/99. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b> <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	10/849,356		
		Filing Date	05-19-2004		
		First Named Inventor	MARY, et. al.		
		Group Art Unit	1623		
		Examiner Name	Not Yet Assigned		
Sheet	2	of	2	Attorney Docket Number	ST00001 - US - CNT

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
LM		Tans, L., et. al., Nadroparin Calcium In Treating Ischemic Cerebral Vascular Disease, Chinese Journal of New Drugs and Clinical Remedies, pp. 325-326 Vol.17, No. 6 (1998)	✓
LM		LI, T., et. al., Observations on Sulodexide's Curative effect on Cerebral Vascular Diseases and the Adverse Drug Reaction Thereof, Chinese Journal of New Drugs (1999), Vol.8, No.6, pp.411-412	✓

Examiner Signature	/Leigh Maier/	Date Considered	07/06/2006
--------------------	---------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.